LOS ANGELES — With NBA free agency approaching in two weeks, the Los Angeles Lakers face critical decisions regarding the future of LeBron James, who has signaled his intention to continue playing and is focused on finalizing a new contract with the team.

James, entering what could be his 24th NBA season, exercised his player option for the current year but now navigates free agency as one of the league’s most prominent available players. Recent reports indicate active discussions between James and the Lakers, with both sides working toward an agreement.

ESPN’s Brian Windhorst provided the latest insight into the situation, noting James’ clear preference to remain in Los Angeles while acknowledging the complexities involved. “I think LeBron’s intention is to play. I think the focus now is on finalizing a deal with the Lakers,” Windhorst said. “Right now, he’s allowed to negotiate with them, and I believe they are negotiating. They are going back and forth.”

The timing adds pressure, as free agency opens soon and other teams could enter the picture if talks stall. Windhorst suggested the Cleveland Cavaliers might show interest as a fallback, but the prevailing view around the league points toward a Lakers resolution.

Financial considerations will play a central role. James’ previous deal carried a substantial cap hit, and any new agreement could influence the Lakers’ ability to pursue additional free agents. The team must balance retaining its veteran superstar with building a competitive roster around him.

James has spent the bulk of his recent career with the Lakers, leading them to a championship in 2020. At 41, he continues to perform at a high level, averaging strong numbers while adapting his game to support younger teammates. His presence remains a major draw for fans and a foundational element for the franchise.

The Lakers’ front office, led by Rob Pelinka, faces a delicate balancing act. Retaining James provides continuity and star power, but salary constraints could limit flexibility in addressing roster needs. Recent seasons have highlighted the importance of complementary pieces around the aging superstar.

Speculation has included potential contract structures, such as shorter deals with player options that offer mutual flexibility. James has historically prioritized winning opportunities alongside financial security, factors likely influencing his decision-making.

Other teams monitoring the situation include those with cap space and contention aspirations. However, James’ deep ties to Los Angeles and the Lakers’ Bird rights advantage make a return the most straightforward path.

The broader NBA landscape adds context. Several star players are expected to hit free agency, creating a competitive market for talent. Teams like the Lakers must move decisively to secure their priorities.

James has evolved into more than just a player, serving as a mentor and leader while maintaining elite performance standards. His potential return would anchor the Lakers’ efforts to build around Anthony Davis and a mix of veterans and young talent.

Fan sentiment remains strongly in favor of keeping James in purple and gold. Social media and sports talk shows have buzzed with discussions about his legacy and the impact of his decision on the franchise’s future trajectory.

As negotiations progress, both sides will weigh short-term roster construction against long-term flexibility. The outcome could shape the Lakers’ competitiveness for years to come.

The coming days will prove pivotal. With free agency looming, resolution on James’ status would allow the Lakers to pivot toward other moves aimed at bolstering their roster. For James, the focus remains on continuing his storied career on his terms.

The California-headquartered business has invested $10m in the Somerset company

A Bath spectacles company has secured a $10m investment from a US technology giant as it looks to develop ‘smart eyewear’.

Inspecs announced a subscription for 7,503,001 new ordinary shares of 1 pence each in the company by Qualcomm Technologies, with the funds used to support its growth.

Inspecs, which recently agreed to be acquired by entrepreneurs Luke Johnson and Ian Livingstone for £85.4m, said the commercial collaboration would create “a connected, technology-enabled platform that intends to redefine eyewear.”

Robin Totterman, founder of Inspecs Group, said: “For many years we have believed that smart eyewear is the next frontier for wearable technology and we are delighted to be partnering with Qualcomm Technologies to deliver on our ambitions.

“We believe this investment and strategic collaboration will accelerate adoption in a category that is about to scale rapidly, and position Inspecs and Qualcomm Technologies among leaders in the industry.”

Qualcomm Technologies is a subsidiary of California-headquartered Qualcomm Group which specialises in the research, development and commercialisation of wireless and computing technologies.

The company has already developed smart eyewear that employs AI under its Snapdragon brand.

Ziad Asghar, senior vice president and general manager of XR, wearables and personal AI at Qualcomm Technologies, said: “Qualcomm Technologies’ collaboration with Inspecs reflects our focus on enabling a new generation of personal AI devices across industries such as enterprise, healthcare, and industrial applications.

“We’re also pleased that Inspecs will be the first partner to adopt our Snapdragon START program, helping bring smart glasses to market that fit naturally into everyday life—blending timeless design with powerful, intuitive technology.”

Inspecs was founded in 1988 by Robin Totterman, a former City bond trader, and now has operations around the world including in the US Portugal, Scandinavia and China, and manufacturing facilities in Vietnam, China and Italy.

SYDNEY — The S&P/ASX 200 index posted modest gains Thursday, supported by strong performances in biotechnology and resources sectors as investors responded to company-specific developments and broader commodity trends.

Biotechnology firm Mesoblast Ltd. led the day’s advances, climbing more than 6 percent amid ongoing interest in its regenerative medicine pipeline. Medical technology company 4DMedical followed with gains exceeding 4 percent, reflecting positive sentiment around innovative healthcare solutions.

Deep Yellow Ltd., a uranium explorer, also featured among the top performers, rising nearly 5 percent as global energy markets showed renewed focus on nuclear power alternatives. These movers highlighted sector rotation toward areas with perceived growth potential amid shifting economic signals.

The benchmark index closed at 8,911.10, down slightly on the day but maintaining resilience near recent highs. Market breadth favored gainers in select industries, though broader caution persisted due to international developments and domestic economic data.

Trading volumes remained healthy as participants assessed corporate earnings and commodity price movements. Resources stocks benefited from stable iron ore and gold prices, while technology and healthcare names drew attention for innovation-driven catalysts.

Analysts noted the market’s selective nature, with investors favoring companies demonstrating clear near-term catalysts over those facing macroeconomic headwinds. The performance of smaller and mid-cap stocks within the ASX 200 underscored this dynamic.

Mesoblast’s advance came as the company continues progress in its stem cell therapies, attracting interest from investors seeking exposure to regenerative treatments. The firm has multiple programs targeting inflammatory and cardiovascular conditions.

4DMedical gained on developments related to its respiratory imaging technology, which offers non-invasive diagnostics for lung diseases. The company’s focus on advanced medical devices aligns with growing demand for precision healthcare tools.

In the resources sector, Deep Yellow’s rise reflected optimism around uranium demand as countries pursue cleaner energy sources. The explorer has projects in Australia and Africa, positioning it to benefit from long-term nuclear power trends.

Other notable performers included companies in gold mining and technology services, though specific details varied by individual announcements and market sentiment. The day’s trading reflected a mix of company news and sector rotation.

Market watchers highlighted the ASX 200’s ability to find support despite mixed global cues. U.S. markets showed varied performance overnight, while commodity prices provided a stabilizing influence for Australian equities.

Economists continue monitoring inflation data and potential Reserve Bank of Australia policy moves. Interest rate expectations have shifted in recent weeks, influencing investor appetite for growth-oriented stocks.

The biotechnology sector has been a standout performer in 2026, driven by innovation in areas like cell and gene therapies. Companies with strong clinical pipelines have attracted capital as investors seek higher-growth opportunities.

Resources stocks remain sensitive to Chinese economic indicators and global supply dynamics. Iron ore and battery minerals have seen fluctuating demand, affecting valuations across the mining sector.

Broader market sentiment stays cautious amid geopolitical uncertainties and corporate earnings variability. Analysts recommend focusing on companies with robust balance sheets and clear strategic plans.

For individual investors, the day’s gainers illustrate the importance of diversification and staying attuned to sector-specific news. While top performers delivered strong returns, the overall index movement was more measured.

Looking ahead, market participants will watch for further corporate updates and macroeconomic releases. The balance between growth sectors and traditional resources will likely continue shaping ASX 200 performance in coming sessions.

This article was written by

Follow

The watchdog says it looked at thousands of documents as part of the probe which had been running since last summer

The Financial Conduct Authority has closed its probe into alleged misreporting of biomass sourcing at Drax.

The watchdog had opened an investigation into the energy firm in August last year, focusing on its accounts between 2021 and 2023. It followed whistleblower allegations stemming from an employment tribunal.

The FCA’s involvement covered Drax’s required disclosures as a listed company. Now the FCA has confirmed the investigation has ended with no further action.

It said: “We undertook an extensive investigation following concerns raised regarding disclosures to the market about the sustainability of Drax’s Canadian biomass. We did not find evidence that justified any further action.

“Thousands of pages of complex material were reviewed as part of the investigation, and individuals from the company interviewed. Our focus was on areas within our remit, specifically whether Drax’s annual reports and accounts between 2021 and 2023 contained misleading statements or left out important information investors needed to know. Accurate reporting is crucial to the integrity of our markets, and vital so investors can make informed decisions.”

Will Gardiner, CEO of Drax said: “We recognise the importance of compliance with our regulatory obligations and have worked constructively with the FCA throughout this investigation. We are pleased to see the investigation closed with no action being taken.”

NEW YORK — Shares of Biohaven Ltd. jumped more than 12 percent Wednesday, closing at $13.62 after climbing on positive momentum surrounding the biotechnology company’s advancing clinical pipeline in immunology, neuroscience and obesity treatments.

The surge came as investors reacted to recent developments in Biohaven’s diverse portfolio, including progress on candidates targeting conditions with significant unmet medical needs. The stock has shown volatility typical of clinical-stage biopharmaceutical companies, trading well below some analyst price targets that suggest substantial upside potential.

Biohaven focuses on discovering, developing and commercializing treatments across multiple therapeutic areas. The company has built on its legacy in migraine therapies while expanding into new platforms such as extracellular protein degradation and ion channel modulation.

Recent positive data from programs like opakalim for epilepsy and candidates in Graves’ disease and IgA nephropathy have contributed to renewed interest. Biohaven reported first-in-human dosing for BHV-8100, an oral PKM2 modulator aimed at metabolic restoration and immunomodulation.

Analysts maintain a generally favorable outlook despite the stock’s current levels. Consensus ratings lean toward Buy, with average price targets around $22 to $28, implying notable potential appreciation from recent trading ranges. Some forecasts reach as high as $50 in optimistic scenarios.

The company reported narrowed losses in its first-quarter 2026 results, supported by careful management of research and development expenses while advancing multiple late-stage programs. Cash reserves stood at approximately $352 million, providing runway for upcoming milestones.

Key upcoming catalysts include pivotal epilepsy data for opakalim and Phase 2 obesity results for taldefgrobep alfa expected in the second half of 2026. Biohaven also plans to initiate pivotal trials for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy by mid-year.

The biotechnology sector has seen heightened activity around innovative platforms. Biohaven’s approach, including antibody drug conjugates for oncology and myostatin inhibitors for obesity, positions it at the intersection of several high-growth areas.

However, risks remain characteristic of the industry. Clinical trial outcomes are inherently uncertain, and regulatory approvals can face delays. Biohaven has highlighted broad operational, financial and market risks in its disclosures, consistent with peers in early-to-mid stage development.

Wall Street firms have offered varied assessments. Some analysts cite strong pipeline potential and de-risking events ahead, while others point to competitive pressures and financing needs. Recent ratings have included reaffirmations of Buy alongside some Hold positions with adjusted price targets.

Biohaven’s market capitalization hovers around $1.8 billion, reflecting its status as a mid-cap player with significant growth ambitions. Trading volume has increased during periods of pipeline news, indicating investor sensitivity to clinical updates.

The company’s strategy emphasizes multiple shots on goal across therapeutic areas, potentially mitigating risks associated with any single program. This diversified approach has drawn comparisons to other successful biopharma innovators.

For investors considering Biohaven, the decision hinges on tolerance for volatility and belief in the pipeline’s eventual translation into approved therapies. Near-term price movements will likely be driven by data readouts and broader market sentiment toward biotechnology.

Analysts project substantial upside in successful scenarios, with some models suggesting more than 100 percent potential returns based on peak sales estimates for leading candidates. Realization of these forecasts depends on positive trial results and effective commercialization.

Biohaven continues to attract attention as a company with one of the industry’s more innovative portfolios. Its progress will be closely watched by investors seeking exposure to next-generation treatments in neurology, immunology and metabolic diseases.

As with any investment in clinical-stage biotech, thorough due diligence and consideration of portfolio diversification remain essential. Biohaven’s trajectory offers both significant opportunity and the uncertainties inherent in drug development.

Helen Fychan has also spoken on devolving broadcasting to Wales.

Culture and sport “are not a nice to have – they are part of the solution to creating a healthier, more prosperous society”, according to Wales’ new culture and sport minister. Outlining her priorities in the Senedd Heledd Fychan highlighted the importance of the arts and sport in preventative health. She also spoke of the importance of the Welsh language and Wales’ music industry, and called for the devolution of broadcasting, “These priorities mark the beginning of a journey and the beginning of a new chapter for culture and sport here in Wales,” Ms Fychan told the Siambr. She continued: “This government believes in the power of culture and sport to transform lives, to contribute to the vision of moving towards a preventative health agenda to put our health service on a more sustainable footing, and because we are determined to build a Wales where creativity thrives.” Ms Fychan, of Pontypridd Cynon Merthyr, was quizzed on her government’s calls for the devolution of broadcasting. In her statement, the minister pledged to create a “stronger media environment” which reflects a “confident and prosperous Wales”. Laying out her priorities for broadcasting, she said: “Wales deserves a confident, diverse and sustainable media landscape rooted in public value and national ambition. “To achieve this, Wales must have a voice in the decisions that affect us. That is why we are determined to continue to make the case for the devolution of powers over broadcasting.” She revealed work is underway to set up a shadow broadcasting and communications authority – designed to build a “stronger and more accountable” media landscape in Wales.

She also highlighted her plans to support public-interest journalism and “safeguard the provision of high-quality news”. Describing the development of a shadow broadcasting authority as “completely unnecessary”, Reform’s Louise Emery – who is shadow minister for culture – said: “This is more constitutional navel-gazing, more quangos, more slow state-building towards independence, and more cost.” Ms Emery went on to criticise the government’s plans to support public-interest journalism and said: “On this side of the chamber, we feel we already have a state-funded news outlet with blatant political bias, and we don’t need any more. “I would suggest that state-funded journalism in Wales will mean state-funded interference, and I would also suggest that ‘high-quality news’ is a highly subjective phrase. Who is going to decide what is high-quality journalism and therefore needs state help?” She added: “How can we ensure there is no foreign interference when allocating Books Council of Wales funding to news outlets?” Ms Emery’s comments were met with laughter in the Siambr from opposing politicians. However, Ms Fychan made no reference to Ms Emery’s comments in her response. Paul Davies, Welsh Conservative spokesperson for the Welsh language, culture and sport, echoed Ms Emery’s criticisms of the devolution of broadcasting powers. Outlining his party’s opposition to broadcasting devolution, Mr Davies said: “Given the challenges that the cabinet minister has already highlighted in her statement today, surely this is not the best possible use of resources, especially given that these powers are not devolved.” Mr Davies called for Ms Fychan to reveal how much was spent on the new authority, how it will be funded, and how it will operate. Similarly as with Ms Emery, Ms Fychan did not reference Mr Davies’ broadcasting comments in her response. Ms Fychan described use of the Welsh language, particularly social use, as an “integral” part of her priorities. Discussing the upcoming Eisteddfod – which is celebrating it’s 850th anniversary – she said: “A contribution of £0.25 million from the government will support a programme of activities to inspire people to use the language and raise the international profile of the National Eisteddfod. “Our financial support will also ensure that local low-income families have free access to the festival. “It is vital that everybody has an opportunity to enjoy our culture, language and National Eisteddfod.” Reform’s shadow minister noted that she was “really glad” to hear the Welsh language was being prioritised. Responding briefly to the cabinet minister in Welsh, Ms Emery shared that she has been learning Welsh for two years and is hoping to practice her skills at the Eisteddfod this summer. However, she questioned Plaid’s plans to get people speaking the language, adding that “coercion drives resentment, not fluency”. She said: “If the Welsh Government is serious about one million Welsh speakers, it needs to invest in the conditions that make people choose the language, not mandate it on those who don’t speak it. “Welsh culture, the arts and sport should lift people up and bring communities together – that we agree on. But they can do that in whatever language they choose.” In her statement, Ms Fychan said: “For too long, culture, the arts and sport have been pitted against the NHS rather than being recognised as completely connected to it. “These sectors are not a ‘nice to have’; they are part of the solution to creating a healthier society. Our manifesto commits to making culture and sport accessible to all. “That includes addressing inequalities in access, whether due to cost, geography, disability or other barriers.” Reform’s shadow minister for health, prevention and sport, James Evans, noted that he “never thought [he’d] find the day” he would agree with the minister on so much. Mr Evans described sport as a “key part” of the prevention agenda, before questioning the minister on how much of the NHS budget will be reallocated to sports. He said: “We’ve heard a lot today about money being moved, but I think a lot of the sports organisations listening to today’s proceedings would like to know exactly what proportion that’s going to be.” In response Ms Fychan said: “In terms of the exact figures and how we will do this, this is a completely new way of working for government, and what I can give you the assurance of is that there is an acknowledgement across government of the importance of this, that we are ensuring that those discussions are now taking place within those first 100 days and we will update the Senedd as we can.” Labour’s Mike Hedges questioned the minister on music tourism and it’s importance to both Welsh culture and the economy. Stating that music touring in Wales, “attracted 834,000 visitors, supported 3,650 jobs, and generated £384 million for the economy” in 2024, Mr Hedges pressed the minister to commit to supporting Welsh music. He said the Welsh Government must “grow Welsh music through smart public investment, bring down barriers to exporting Welsh music, ensure music education is accessible to all, and support home-grown creativity and new music that drives Welsh tourism”. In response, Ms Fychan referenced a report released last year which showed that traditional music in Wales was in danger of “disappearing entirely”. Noting that fewer children are taking GCSEs in music, drama, and art and that universities are cutting courses in creative areas, Ms Fychan said often these areas are seen as “not worth investing in” – adding that, “of course”, they are. Closing her response to the member she said: “Hopefully we will then see, […], that there will be a future for creative people here in Wales, and a future for these sectors that are seen as economically beneficial.”